chr1-11129799-C-T
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 2P and 11B. PM1BP4_ModerateBP6BS1BS2
The NM_004958.4(MTOR):c.5653G>A(p.Val1885Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000304 in 1,614,172 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_004958.4 missense
Scores
Clinical Significance
Conservation
Publications
- macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Illumina, Orphanet, Labcorp Genetics (formerly Invitae), G2P
- overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genesInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -9 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000315 AC: 48AN: 152208Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000342 AC: 86AN: 251424 AF XY: 0.000353 show subpopulations
GnomAD4 exome AF: 0.000302 AC: 442AN: 1461846Hom.: 2 Cov.: 30 AF XY: 0.000272 AC XY: 198AN XY: 727214 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000315 AC: 48AN: 152326Hom.: 0 Cov.: 32 AF XY: 0.000416 AC XY: 31AN XY: 74478 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Benign:3
- -
MTOR: BS1, BS2 -
- -
Isolated focal cortical dysplasia type II;C4225259:Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome Uncertain:1
- -
not specified Benign:1
DNA sequence analysis of the MTOR gene demonstrated a sequence change, c.5653G>A, in exon 40 that results in an amino acid change, p.Val1885Ile. This sequence change does not appear to have been previously described in individuals with MTOR-related disorders and has been described in the gnomAD database with a frequency of 0.053% in the European sub-population (dbSNP rs139043855). The p.Val1885Ile change affects a highly conserved amino acid residue located in a domain of the MTOR protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Val1885Ile substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Val1885Ile change remains unknown at this time. -
Inborn genetic diseases Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
MTOR-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at